Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Our network meta-analysis analyzed the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on fracture risk. By combining data from randomized controlled trials, we found that GLP-1 RAs were associated with a decreased bone fracture risk, and exenatide is the best option agent with regard to the risk of fracture. This study is registered with PROSPERO (CRD42018094433). Introduction Data on the effects of GLP-1 RAs on fracture risk are conflicted. This study aimed to analyze the available evidence on the effects of GLP-1 RAs on fracture risk in type 2 diabetes mellitus patients. Methods Electronic databases were searched for relevant published articles, and unpublished studies presented at ClinicalTrials.gov were searched for relevant clinical data. All analyses were performed with STATA 12.0 and R software (Version 3.4.4). We estimated the risk ratio (RR) and 95% confidence interval (CI) by combining RRs for fracture effects of included trials. Results There were 54 eligible random control trials (RCTs) with 49,602 participants, including 28,353 patients treated with GLP-1 RAs. Relative to placebo, exenatide (RR, 0.17; 95% CI 0.03-0.67) was associated with lowest risk of fracture among other GLP-1 RAs. Exenatide had the highest probability to be the safest option with regard to the risk of fracture (0.07 ‰), followed by dulaglutide (1.04%), liraglutide (1.39%), albiglutide (5.61%), lixisenatide (8.07%), and semaglutide (18.72%). A statistically significant incons…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meta-analyses examining the relationship between fracture risk and incretin therapies in patients with diabetes have yielded inconsistent results, often hindered by the limited number of fracture occurrences, short treatment durations, absence of BMD evaluations, and influence of other diabetes medications (46,47).”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [46]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207 · cited 1×
“To account for heterogeneity between studies [11, 12], we used the random effects model for the Bayesian network metaanalysis to evaluate the relative risk ratios (RR) of GLP-1 RAs and other anti-diabetes on bone fracture, allowing both direct and indirect evidence to be taken into account simulta-”
MethodDemystifying trial networks and network meta-analysis
Mills, E. J., Thorlund, K., & Ioannidis, J. P. A. (2013) · BMJ · doi:10.1136/bmj.f2914 · Cited by 742
Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes
Schwartz, A. V. (2011) · JAMA · doi:10.1001/jama.2011.715 · Cited by 717
van Valkenhoef, G., Dias, S., Ades, A. E., & Welton, N. J. (2016) · Research Synthesis Methods · doi:10.1002/jrsm.1167 · Cited by 695
Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study.
de Liefde, I. I., van der Klift, M., de Laet, C. E. D. H., van Daele, P. L. A., Hofman, A., & Pols, H. A. P. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1909-1 · Cited by 555
Cited by
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Impact of Diabetes Mellitus on Bone Health
Murray, C. E., & Coleman, C. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194873 · Cited by 228
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis
Zhang, Y.-S., Zheng, Y.-D., Yuan, Y., Chen, S.-C., & Xie, B.-C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735824 · Cited by 117
Self-citation
Metadata
- Authors
- Zhang, Y. S., Weng, W. Y., Xie, B. C., Meng, Y., Hao, Y. H., Liang, Y. M., & Zhou, Z. K.
- Affiliations
- Guangdong Medical College (CN)
- Corresponding author
- Zhou, Z. K.
- Venue
- Osteoporosis International
- Published
- 2018-08-06
- Volume
- 29
- Issue
- 12
- Pages
- 2639-2644
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2885062261
- Cited by
- 93
- References
- 23
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 14 · 2023: 9 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 9 · 2018: 2
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81774344)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, fracture risk, exenatide, type 2 diabetes, dulaglutide, liraglutide, albiglutide, lixisenatide, semaglutide, osteoporosis, drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Network Meta-Analysis, Bayes Theorem, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Osteoporotic Fractures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1007/s00198-018-4649-8
- The paper
- Zhang, Y. S., Weng, W. Y., Xie, B. C., Meng, Y., Hao, Y. H., Liang, Y. M., & Zhou, Z. K. (2018). Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporosis International. https://doi.org/10.1007/s00198-018-4649-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.